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Continuing lack of evidence for the psychotic
subtyping of PTSD
Gaudiano & Zimmerman1 conclude that psychotic symptoms in
post-traumatic stress disorder (PTSD) are associated with
comorbid conditions, especially major depressive disorders, and
that their results therefore do not support the existence of a
psychotic subtype of PTSD. However, they did not evaluate certain
factors that might be responsible for misinterpretation of their
results. First, they did not report the severity of post-traumatic
and depressive symptoms. It is possible that patients with
PTSD without comorbid depressive disorder had a milder post-
traumatic disorder and consequently less probability of presenting
with psychotic symptoms. Second, in clinical practice the
congruence of delusions and hallucinations with traumatic events
seems to be distributed across a continuum: at one extreme there
is complete congruence with trauma and at the other there are
exuberant and bizarre symptoms similar to those described in
schizophrenia. The elucidation of the possible existence of a
psychotic subtype of PSTD must necessarily include the
development of adequate instruments to measure severity and
congruence of psychotic symptoms in ‘non-psychotic’ conditions
(e.g. mood and anxiety disorders), as well as their biological
correlates.
1 Gaudiano BA, Zimmerman M. Evaluation of evidence for the psychotic
subtyping of post-traumatic stress disorder. Br J Psychiatry 2010; 197: 326–7.
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Authors’ reply: We welcome the response by Brietzke and
colleagues to our report. First, they suggest that differences in
illness severity between those with v. those without the
comorbidities we excluded might have accounted for reductions
in the prevalence rate of psychotic symptoms in our sample. To
help address this point, we reanalysed our data by conducting a
logistic regression of data for PTSD patients with v. without the
excluded comorbidities as a predictor of the likelihood of having
psychotic symptoms while controlling for Global Assessment of
Functioning scores. Comorbid status remained a significant
predictor. It is important to clarify we did not exclude all
comorbidities from the PTSD sample: we removed only those that
also allow for the presence of psychotic symptoms (e.g.
schizophrenia, bipolar disorder). Other comorbid diagnoses
(e.g. anxiety disorders) remained in the refined PTSD sample
showing the low prevalence of psychosis. Therefore, we do not
believe that differences in illness severity can adequately explain
our findings.
Second, Brietzke et al point out that psychotic symptoms in
PTSD probably fall along a spectrum from congruent (e.g.
hallucinations related to vivid re-experiencing of the trauma) to
non-congruent (e.g. bizarre, non-trauma-related hallucinations).
We agree with this observation in general, but disagree that
congruence criteria are likely to clarify these issues from a
diagnostic standpoint. The distinction between congruent v.
non-congruent psychotic symptoms in primary mood disorders
is known to lack prognostic value and patients frequently exhibit
characteristics of both at the same time.1
We agree with Rosen & Lilienfeld2 that continued conceptual
confusion regarding the PTSD diagnosis suggests the need for
greater caution, rather than a rush to expand the criteria to
encompass larger groups of clinical presentations, until the
validity of the core features of the PTSD diagnosis can be better
established. We also disagree with Breitzke et al that investigations
of biological correlates of PTSD are likely to shed much more light
on these issues. Extensive previous research in this area has found
a lack of evidence for biomarkers linked specifically to the PTSD
diagnosis as opposed to those that cut broadly across diagnostic
categories and clinical presentations.2
1 Gaudiano BA, Uebelacker LA, Miller IW. Course of illness in psychotic mania:
is mood congruence important? J Nerv Ment Dis 2007; 195: 226–32.
2 Rosen GM, Lilienfeld SO. Posttraumatic stress disorder: an empirical
evaluation of core assumptions. Clin Psych Rev 2008; 837: 837–68.
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Is transference-focused psychotherapy really
efficacious for borderline personality disorder?
In their study of treatment for borderline personality disorder,
Doering et al state that their results ‘demonstrate the significant
superiority of transference-focused psychotherapy with regard to
the primary outcome criteria of drop-out rate and suicide
attempts during the treatment year’ when compared with
treatment by experienced community psychotherapists.1 They
report that ‘significantly fewer participants dropped out of the
transference-focused psychotherapy group (38.5% v. 67.3%) and
also significantly fewer attempted suicide (d= 0.8, P=0.009)’.
In our view, this interpretation of primary outcome criteria
might lead to misunderstandings. As regards suicidality, the
authors suggest that the P-value of 0.009 would relate to absolute
numbers of attempted suicides during the treatment year.
However, the actual difference in suicide attempts during the
treatment year (7/52 v. 11/52) is not significant (P= 0.44,
continuity-corrected w2-test, LOCF analysis). The significant
P-value reported by the authors seems to correspond to change
scores (defined as 1/0/71 by the authors), not to suicide attempts
during the treatment year, which seems to be the outcome as
defined in the study protocol (trial NCT00714311). The authors
further suggest that the effect size of 0.8 would refer to the
between-group comparison. However, the reported effect size
seems to correspond to the within-group comparisons reported
in Table DS2. The between-group effect size for suicide attempts
during the treatment year would be small.
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The other primary outcome to assess efficacy was defined as
the rate of participants not receiving the allocated treatment plus
the rate of participants who discontinued the allocated treatment.
Even when accepting that patients not even starting treatment
were included in a measure of treatment efficacy, it seems
problematic to ascribe differences in this criterion to the efficacy
of transference-focused psychotherapy without excluding
accumulative effects of alternative explanations. The higher rate
of non-starters among patients randomised to community
therapists (the control condition) compared with those
randomised to transference-focused psychotherapy (25% v.
13%) and the substantially higher rate of patients stopping
treatment in the control group within the first month (Fig. 2 of
the paper) might reflect a general preference of participants for
transference-focused psychotherapy rather than its superior
efficacy. Furthermore, the authors have not mentioned that this
criterion combining non-starters and ‘drop-outs’ as primary
outcome of efficacy was introduced post hoc (for post-hoc
changes in the definition of primary outcome criteria see http://
clinicaltrials.gov/archive/NCT00714311). Without addressing this
issue, the statistical implications of this proceeding are difficult
to evaluate.
As for the secondary outcome measures, the picture seems to
be mixed. Some of the LOCF analyses indicated lower scores after
transference-focused psychotherapy (e.g. number of borderline
criteria, level of personality organisation). Other scores (e.g.
general psychopathology, depression) were numerically higher
after transference-focused psychotherapy and did not improve
significantly more under it (P=0.92 and P=0.85 for general
psychopathology and depression respectively).
Recapitulating, it seems that the claimed efficacy of
transference-focused psychotherapy does not follow from the
primary outcome criteria. Accordingly, further research seems
necessary to establish the efficacy of this therapy in the treatment
of borderline personality disorder.
1 Doering S, Ho¨rz S, Rentrop M, Fischer-Kern M, Schuster P, Benecke C,
et al. Transference-focused psychotherapy v. treatment by community
psychotherapists for borderline personality disorder: randomised controlled
trial. Br J Psychiatry 2010; 196: 389–95.
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Author’s reply: Kleindienst and colleagues argue that our
interpretation of the treatment outcome with regard to suicide
attempts might lead to misunderstandings. They are right that a
w2-test comparing the absolute number of suicide attempters in
both groups, transference-focused psychotherapy and treatment
by experienced community psychotherapists, is not significant.
However, this test does not seem appropriate in the present
context, since the baseline, that is the number of suicide
attempters during the year before treatment, was not equal in both
groups (18 in the transference-focused psychotherapy group v. 12
in the community psychotherapists group). Thus, a statistical
approach had to be employed that controls for baseline data. Since
no w2-test exists that controls for baseline values, we defined
change scores that allow for baseline control within a Mann–
Whitney U-test. This test generated the P= 0.009 that, in our
opinion, depicts the real changes in suicide attempters in both
groups. A between-group effect size of 0.55 for the time6group
interaction in suicide attempts was calculated from the
w2-statistics of the change scores (w2 = 7.126, d.f. = 2, P50.028).
Table DS2 of our paper only reports within-group effect sizes;
between-group effect sizes were not calculated.
The issue of treatment drop-out is a limitation of this study,
which has been thoroughly controlled for and discussed in our
paper. After the decision to use treatment drop-out as a primary
outcome criterion, we preferred to keep strictly to the intent-to-
treat algorithm that demands every randomised patient to be part
of the outcome analysis. Nevertheless, to address the under-
standable criticism raised by Kleindienst and colleagues, we
repeated the drop-out analysis after excluding from it patients
who did not begin therapy after randomisation. This analysis still
revealed a significantly lower number dropping out of the
transference-focused psychotherapy group (15 v. 23; w2 = 5.750,
d.f. = 1, P= 0.016).
The changes in the primary outcome criteria had been made
following the impression of an ongoing discussion in the literature
addressing the adequacy of DSM–IV diagnostic criteria as
outcome criteria in treatment studies.1,2 Since our initial outcome
criteria ‘number of DSM–IV borderline criteria’ and ‘GAF score’
revealed an even stronger superiority of transference-focused
psychotherapy, we did not report this post-hoc change, because a
bias in our decision was not suspected.
We thank Kleindienst and colleagues for their criticism and
the Editor for giving us the opportunity to clarify important issues
regarding our study. We hope that our comments will eliminate
doubts concerning the fact that our study documents the efficacy
of transference-focused psychotherapy for the treatment of
borderline personality disorder.
1 Skodol AE, Pagano ME, Bender DS, Shea MT, Gunderson JG, Yen S, et al.
Stability of functional impairment in patients with schizotypal, borderline,
avoidant, or obsessive–compulsive personality disorder over two years.
Psychol Med 2005; 35: 443–51.
2 Zanarini MC, Frankenburg FR, Reich DB, Silk KR, Hudson JI, McSweeney LB.
The subsyndromal phenomenology of borderline personality disorder:
a 10-year follow-up study. Am J Psychiatry 2007; 164: 929–35.
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Ziprasidone and the relative risk of diabetes
Kessing et al1 describe the risks of diabetes in clinical practice from
a large-cohort, observational study of Danish patients requiring
antipsychotics. We believe that the relative risks of subsequent
incident diabetes that they report for individual antipsychotics
are at odds with established literature. The preponderance of
evidence has demonstrated that ziprasidone has limited effect on
metabolic indices associated with the development of diabetes.
We present some of that evidence below.
In the CATIE study of 1493 patients with schizophrenia
receiving olanzapine, quetiapine, risperidone, ziprasidone or
perphenazine for up to 18 months, ziprasidone was the only drug
associated with improvement in glycosylated haemoglobin, total
cholesterol and triglycerides. Meyer and colleagues2 reported that,
in the CATIE trial, the prevalence of metabolic syndrome
increased for olanzapine (from 34.8% to 43.9%) but decreased
for ziprasidone (from 37.7% to 29.9%), and that the comparison
between ziprasidone and olanzapine was statistically significant
(P=0.001).
In the EUFEST study of 498 patients with first-episode
schizophrenia assigned to haloperidol, amisulpride, olanzapine,
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quetiapine or ziprasidone for 12 months, weight change was
greatest on olanzapine and among the lowest on ziprasidone.3
Ziprasidone was not associated with untoward effects on any other
metabolic risk factors.
A pooled analysis in 2009 of over 100 Pfizer-sponsored
randomised controlled trials found no significant differences
between 1605 individuals given ziprasidone and 677 given placebo
in total cholesterol, fasting glucose or fasting triglycerides (details
available on request).
Yood et al,4 in a 55 287-member inception cohort of
antipsychotic users, found 357 cases of newly treated diabetes.
Ziprasidone was among the group of agents with the lowest risk
of diabetes. Patients exposed to olanzapine and clozapine had
an increased risk of the illness.
A consensus statement on antipsychotic drugs and obesity
published by the American Diabetes Association et al in 2004
concluded that increased risks of obesity, dyslipidaemia and
diabetes are most associated with clozapine and olanzapine; little
or no significant weight gain, diabetes and dyslipidaemia was
associated with aripiprazole and ziprasidone, although it should
be noted that these agents had not yet been used extensively at that
time.5 Further, the panel suggested switching patients who
develop worsening glycaemia or dyslipidaemia to a second-
generation antipsychotic not associated with significant weight
gain or diabetes (i.e. ziprasidone or aripiprazole). Standards of
practice that promote agents with lower metabolic risks may be
a confounding factor in naturalistic studies.
Kessing et al acknowledge that ‘individuals at higher risk of
diabetes because of a personal history of obesity or inactivity, a
family history of diabetes or other risk factors may have been
prescribed agents perceived to confer a lower risk of diabetes’. This
channelling bias affects the generalisability of their results.
They report a low risk of diabetes for aripiprazole, but the
drug did not becoming commercially available in Denmark until
2004, only 1.5 years before the end of this 10-year study. A small
number of patients were exposed for a limited period of time,
making the direct comparison with ziprasidone not meaningful.
With regard to Table 3, given the widely differing times of
drug exposure and the ultimate position of any individual agent
within a single patient’s treatment regimen, conclusions about
the risk of an individual agent v. a drug class may be inappropriate
based on this study design.
We are concerned about how clinicians will interpret Kessing
et al’s findings for ziprasidone, as the results stand in contrast to
the relative risks for diabetes reported in the established literature.
1 Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with
antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry
2010; 197: 266–71.
2 Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al.
Change in metabolic syndrome parameters with antipsychotic treatment in
the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res
2008; 101: 273–86.
3 Kahn R, Fleischhacker WW, Karayal O, Siu C, Pappadopulos E, EUFEST
Study Group (2009) EUFEST: the effects of first and second generation
antipsychotics on metabolic and cardiovascular risk factors. In American
Psychiatric Association 162nd Annual Meeting, 2009 New Research
Abstracts, Abstract NR1-043. APA, 2009.
4 Yood MU, DeLorenze G, Quesenberry, CP Jr, Oliveria SA, Tsai AL, Willey VJ,
et al. The incidence of diabetes in atypical antipsychotic users according to
agent – results from a multisite epidemiologic study. Pharmacoepidemiol
Drug Saf 2009; 18: 791–9.
5 American Diabetes Association, American Psychiatric Association, American
Association of Clinical Endocrinologists, North American Association for the
Study of Obesity. Consensus Development Conference on Antipsychotic
Drugs and Obesity and Diabetes (consensus statement). Diabetes Care 2004;
27: 596–601.
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Authors’ reply: We thank Dr Vanderburg and colleagues for
their comments on our paper. We used observational, non-ran-
domised, routinely collected data to describe the rate of incident
diabetes among patients treated with antipsychotics in clinical
practice. These data reflect the way antipsychotics are handled
by individual clinicians on the basis of their knowledge of effects
and side-effects for the specific patient. Findings from analyses of
our data cannot be used to infer causality between individual anti-
psychotics and diabetes and may be at odds with findings from
randomised trials and other studies aimed at testing specific
hypotheses. Our results on the individual antipsychotics describe
the prevalence of diabetes among patients for whom the clinician
decided to prescribe a given antipsychotic.
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